Uropath is a specialist pathology practice established in 1998 and devoted to the diagnosis of urological disorders and malignancies. Based in Perth, Western Australia, the company provides pathology to over 25 urologists and their patients. Uropath employs the most comprehensive laboratory techniques and detailed reporting to ensure the most accurate diagnosis can be made.
The company was founded by Directors Dr Ronald Cohen and Phillip Golding. Dr Cohen has over 20 years experience specialising in urological pathology and is a leading consultant in his field. He is supported by a team of two specially trained urological pathologists, Dr Clifton Woods and Dr Stephen Lee, and associated support staff.
To support Uropath’s services, the company maintains an in-house research team designed to address key issues in urologic disorders and malignancies of the prostate, bladder and kidney. Current research is predominantly population-based, with a focus on prostate cancer. Uropath has developed a number of risk assessment tools (nomograms) which specialists use to improve patient decision-making regarding their prostate cancer. These tools have been adopted by urologists and patients both locally and internationally. The company’s research receives the support of the West Australian Urologic Research Organisation, a committee established and run by the urological community, AbbVie Australia and the Hollywood Research Foundation & Ethics Committee.